Scandion Oncology A/S (“Scandion Oncology”) announces that the results from the 4 SCO-101 phase I clinical trials have been published (https://doi.org/10.1111/bcpt.13466) in the International peer-reviewed journal” Basic & Clinical Pharmacology & Toxicology”.
“An important part of drug development is to publish the results from the different development phases in order to allow a more detailed evaluation of the development. I am very happy that we can now present the data from the 4 clinical phase I studies that were performed by the former owner of SCO-101. As previously announced, SCO-101 as a daily tablet is a safe treatment with only very limited toxicity and a good pharmacokinetic profile (long half-life in the body). We presented all these phase I results to the Danish Medicines Agency as part of our application to start a clinical phase II study in patients with metastatic and drug resistant colorectal cancer” says Nils Brünner, CEO of Scandion Oncology. “We have been extremely satisfied with the collaboration with Department of Clinical Pharmacology at Odense University Hospital in Denmark” Nils Brünner continues.
Scandion Oncology is currently in its first phase 2 study with colorectal cancer patients with acquired resistance toward cancer treatment. “Data from the first cohort of the part 1 of the study is expected to be released during July 2020 and our next clinical study with pancreatic cancer patients is expected to be initiated in the fall of 2020, says Nils Brünner, CEO of Scandion Oncology.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on July 11, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: http://www.scandiononcology.com.